MedTrace Logo

Alpha-Linolenic Acid and Inflammatory Markers

NCT00967733 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2023-12-19

No results posted yet for this study

Summary

The optimal type of oil to prevent cardiovascular disease (CVD) is uncertain. In general, unsaturated oils with higher content of cis-monounsaturated fatty acids (MONO) or cis-polyunsaturated fatty acids (PUFA) are preferable over those rich in saturated fatty acids. However, unsaturated oils can vary in their relative contents of n-6 and n-3 fatty acids (specifically alpha-linolenic acid (ALA)). Some investigators advocate that oils rich in ALA are cardioprotective, while others suggest that optimal cardioprotective effects can only be obtained when oils are lower in n-6 fatty acids (mainly linoleic acid) in addition to being higher in ALA. It is hypothesized that increased ALA would result in beneficial effects on inflammatory markers. The objective of this trial is to establish definitively the biological effects of ALA with and without reductions in linoleic acid on inflammatory markers linked to CVD.

Conditions

Interventions

DIETARY_SUPPLEMENT

Flaxseed oil-Olive oil

2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking

DIETARY_SUPPLEMENT

Olive oil-olive oil

1 gr olive oil pill and olive oil used for cooking

DIETARY_SUPPLEMENT

Flaxseed oil-sunflower oil

2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking

DIETARY_SUPPLEMENT

Olive oil-sunflower oil

1 gr olive oil pill and sunflower oil used for cooking

Sponsors & Collaborators

  • Harvard School of Public Health (HSPH)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-08-31
Completion
2009-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967733 on ClinicalTrials.gov